

European Aviation Safety Agency

**Acceptable Means of
Compliance
and
Guidance Material
to Part-MED**

Amendment 1
8 August 2013¹

¹ For the date of entry into force of this amendment, refer to Decision 2013/016/R in the [Official Publication](#) of the Agency.

AMC TO PART-MED AMENDMENT 1 – CHANGE INFORMATION

The text of the amendment is arranged to show deleted, new or amended text as shown below:

1. deleted text is marked with ~~strike through~~;
2. new or amended text is highlighted in grey; and
3. an ellipsis (...) indicates that the remaining text is unchanged in front of or following the reflected amendment.

Amendments

Create a new AMC17 MED.B.095 and a new AMC18 MED.B.095 directly after existing AMC16 MED.B.095 as follows at:

- AMC to Part-MED
 - Subpart B Specific Requirements for class 1, class 2 and LAPL medical certificates
 - AMC for class 1, class 2 and LAPL medical certificates
 - Section 4 Specific requirements for LAPL medical certificates

AMC17 MED.B.095 Dermatology

In cases where a dermatological condition is associated with a systemic disease, full consideration should be given to the underlying illness before a fit assessment may be considered.

AMC18 MED.B.095 Oncology

- (a) In the case of malignant disease, applicants may be considered for a fit assessment if:
- (1) there is no evidence of residual malignant disease likely to jeopardise flight safety;
 - (2) time appropriate to the type of tumour has elapsed since the end of primary treatment;
 - (3) the risk of in-flight incapacitation from a recurrence or metastasis is sufficiently low;
 - (4) there is no evidence of short or long-term sequelae from treatment that may adversely affect flight safety.
- (b) Arrangements for an oncological follow-up should be made for an appropriate period of time.

...